What is the prevalence of Hereditary multiple exostoses?

Hereditary multiple exostoses (HME) is a rare genetic bone disorder with an estimated global prevalence ranging from 1 in 50,000 to 1 in 100,000 individuals. While incidence and prevalence data are difficult to pinpoint precisely due to varying clinical severity, it is consistently classified as a rare disease affecting both males and females, typically manifesting during early childhood.

What is the estimated prevalence and incidence of Hereditary multiple exostoses?

Determining the exact prevalence of Hereditary multiple exostoses is challenging, as the clinical presentation varies significantly from patient to patient. According to data from Orphanet and the NIH Genetic and Rare Diseases Information Center (GARD), the estimated prevalence is approximately 1 in 50,000 to 1 in 100,000 people. Because many individuals with mild symptoms may never seek medical evaluation, these figures are likely underestimates. The incidence—the number of new cases diagnosed per year—is rarely tracked with precision due to the condition's hereditary nature and the tendency for diagnosis to occur only when symptoms like pain or deformity appear.

Does Hereditary multiple exostoses affect genders and age groups differently?

Hereditary multiple exostoses is an autosomal dominant disorder, meaning it is passed down through families with an equal probability of affecting males and females. While both genders are affected, some clinical literature suggests that males may experience more severe skeletal deformities, though this remains a subject of ongoing study. Regarding age of onset, the condition is primarily pediatric; approximately 80% to 90% of individuals with Hereditary multiple exostoses are diagnosed by the age of 12. New exostoses (bony growths) typically stop forming once skeletal maturity is reached, usually in late adolescence or early adulthood.

Are there geographic or ethnic variations in the prevalence of Hereditary multiple exostoses?

There is no strong evidence suggesting that Hereditary multiple exostoses is more prevalent in specific ethnic groups or geographic regions. However, rare disease data collection remains inconsistent globally. In the DiseaseMaps.org community, 266 individuals have joined to share their experiences with Hereditary multiple exostoses, providing a vital, real-world perspective that complements clinical databases. This community data underscores that while the condition is considered rare, patients are connected across diverse backgrounds, highlighting the importance of global registries in capturing the true scope of the disease.

Why is accurate prevalence data for Hereditary multiple exostoses difficult to obtain?

The primary challenge in establishing accurate statistics for Hereditary multiple exostoses is the phenomenon of variable expressivity. Factors contributing to this include:

• Asymptomatic carriers: Some individuals carry the genetic mutation but have such small or few exostoses that they never require clinical care.


• Diagnostic delays: Mild cases are often misdiagnosed or overlooked until a growth causes a secondary issue, such as nerve compression or restricted joint mobility.


• Under-reporting: Many rare disease registries rely on voluntary reporting, which may not capture individuals who are managed solely by primary care physicians without specialized referral.


• Genetic heterogeneity: Mutations in the EXT1 and EXT2 genes are the primary drivers, but the lack of universal genetic screening means many cases remain clinically diagnosed rather than molecularly confirmed.

Next steps

• Consult with a medical geneticist to discuss family history and potential genetic testing for EXT1 or EXT2 mutations.


• Schedule regular orthopedic monitoring, especially during childhood growth spurts, to track the development of exostoses.


• Connect with the 266 members of the DiseaseMaps.org community to share lived experiences and coping strategies.


• Seek guidance from a specialized center for skeletal dysplasias if you are experiencing pain, limited range of motion, or significant limb length discrepancies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Hereditary multiple exostoses (ORPHA:323).


• NIH Genetic and Rare Diseases Information Center (GARD): Hereditary multiple exostoses.


• OMIM (Online Mendelian Inheritance in Man): Multiple Exostoses, Hereditary, 1 (EXT1).


• DiseaseMaps.org: Community data and patient insights.